First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

被引：19
|
作者：
Roohullah, Aflah
Ganju, Vinod
Zhang, Faming
Zhang, Lei
Yu, Ting
Wilkinson, Kate
Cooper, Adam
de Souza, Paul
机构：
[1] South Western Sydney LHD, Liverpool, Australia
[2] Peninsula & Southeast Oncol, Frankston, Vic, Australia
[3] HanX Biopharmaceut Inc, Hangzhou, VA, Peoples R China
[4] Sydney Southwest Private Hosp, Liverpool, NSW, Australia
[5] St George Private Hosp, Liverpool, NSW, Australia
[6] St George Private Hosp, Kogarah, NSW, Australia
[7] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2517
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2517
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
    Day, Daphne
    Park, John J.
    Coward, Jermaine
    Markman, Ben
    Lemech, Charlotte
    Kuo, James C.
    Prawira, Amy
    Brown, Michael P.
    Bishnoi, Sarwan
    Kotasek, Dusan
    Strother, R. Matthew
    Cosman, Rasha
    Su, Rila
    Ma, Yiding
    Yue, Zenglian
    Hu, Hui-han
    Wu, Rachel
    Li, Peiqi
    Tse, Archie N.
    BRITISH JOURNAL OF CANCER, 2023, 129 (10) : 1608 - 1618
  • [22] A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors
    Deva, Sanjeev
    Zhou, Caicun
    Bishnoi, Sarwan K.
    Lau, Peter Kar Han
    Tran, Ben
    Ba, Yi
    Galsky, Matt D.
    Wang, Yongsheng
    Zhang, Yanqiao
    Luo, Suxia
    Chang, Victoria
    Yu, Cunjing
    Zhang, Teresa
    Zhang, Heather
    Ma, Jiafang
    Naicker, Kirsha May
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors
    Liu, Rujiao
    Li, Wenhua
    Meng, Yanchun
    Gao, Shuiping
    Zhang, Jian
    Hu, Xichun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [24] Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
    Coward, Jermaine
    Mislang, Anna Rachelle Austria
    Frentzas, Sophia
    Lemech, Charlotte Rose
    Nagrial, Adnan
    Jin, Xiaoping
    Li, Baiyong
    Wang, Zhongmin Maxwell
    Kwek, Kon Yew
    Xia, Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
    Frentzas, Sophia
    Mislang, Anna Rachelle Austria
    Lemech, Charlotte
    Nagrial, Adnan
    Underhill, Craig
    Wang, Wenjing
    Wang, Zhongmin Maxwell
    Li, Baiyong
    Xia, Yu
    Coward, Jermaine I. G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [26] First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
    Shitara, Kohei
    Uehai, Satoshi
    Shichino, Shigeyuki
    Aoki, Hiroyasu
    Ogiwara, Haru
    Nakatsura, Tetsuya
    Suzuki, Toshihiro
    Shimomura, Manami
    Yoshikawa, Toshiaki
    Shoda, Kayoko
    Kitano, Shigehisa
    Yamashita, Makiko
    Nakayama, Takayuki
    Sato, Akihiro
    Kuroda, Sakiko
    Wakabayashi, Masashi
    Nomura, Shogo
    Yokochi, Shoji
    Ito, Satoru
    Matsushima, Kouji
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 : 195
  • [27] A first-in-human phase dose-escalation study of YH002, a recombinant humanized agonistic anti-OX40 IgG1 monoclonal antibody, in patients with advanced solid tumors.
    Ganju, Vinod
    Cooper, Adam
    Wilkinson, Kate
    Park, John J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A first-in-human phase 1 study of TQB2916, a novel CD40 agonist antibody for advanced malignancies
    Ba, Yi
    Zhang, Huilai
    Deng, Ting
    Ning, Tao
    Fan, Qian
    CANCER RESEARCH, 2024, 84 (07)
  • [29] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies
    Ribrag, Vincent
    Iglesias, Lara
    De Braud, Filippo
    Ma, Brigette
    Yokota, Tomoya
    Zander, Thomas
    Spreafico, Anna
    Subbiah, Vivek
    Illert, Anna L.
    Tan, Daniel
    Santoro, Armando
    Munster, Pamela N.
    Suehiro, Youko
    Wang, Yongsheng
    Ji, Dong-Mei
    Chen, Shuqi
    Beltz, Karen
    Suenaga, Naoko
    Ramkumar, Thiruvamoor
    Luo, Fangjun
    Lai, Clinton
    Wainberg, Zev A.
    EUROPEAN JOURNAL OF CANCER, 2025, 216
12345